Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655599 · ClinicalTrials.gov registry record · Phase 1
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1 study, sponsored by Arena Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04655599: Clinical Trial Phase 1 study, sponsored by Arena Pharmaceuticals.
NCT04655599 is a Phase 1 study that was terminated before completion, run by Arena Pharmaceuticals. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04655599, a Phase 1 study, was terminated before completion, sponsored by Arena Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
Interventions
- DRUG Placebo
- DRUG Olorinab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2021-04-13 |
| Phase | Phase 1 |
Why NCT04655599 stopped before completion
NCT04655599 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04655599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04655599 about?
NCT04655599 is a clinical study titled "Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome". A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
What is the current status of trial NCT04655599?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2021-01-29. Estimated completion is 2021-04-13.
What interventions are being tested in trial NCT04655599?
The interventions under investigation include: Placebo (DRUG), Olorinab (DRUG).
Who is sponsoring clinical trial NCT04655599?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04655599's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI